TY - JOUR
T1 - International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
AU - Cavo, Michele
AU - Rajkumar, S. Vincent
AU - Palumbo, Antonio
AU - Moreau, Philippe
AU - Orlowski, Robert
AU - Bladé, Joan
AU - Sezer, Orhan
AU - Ludwig, Heinz
AU - Dimopoulos, Meletios A.
AU - Attal, Michel
AU - Sonneveld, Pieter
AU - Boccadoro, Mario
AU - Anderson, Kenneth C.
AU - Richardson, Paul G.
AU - Bensinger, William
AU - Johnsen, Hans E.
AU - Kroeger, Nicolaus
AU - Gahrton, Gösta
AU - Bergsagel, P. Leif
AU - Vesole, David H.
AU - Einsele, Hermann
AU - Jagannath, Sundar
AU - Niesvizky, Ruben
AU - Durie, Brian G.M.
AU - Miguel, Jesus San
AU - Lonial, Sagar
PY - 2011/6/9
Y1 - 2011/6/9
N2 - The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.
AB - The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.
UR - http://www.scopus.com/inward/record.url?scp=79959398524&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-02-297325
DO - 10.1182/blood-2011-02-297325
M3 - Review article
C2 - 21447828
AN - SCOPUS:79959398524
SN - 0006-4971
VL - 117
SP - 6063
EP - 6073
JO - Blood
JF - Blood
IS - 23
ER -